HIV / AIDS

Improving clinical care and outcomes among those with and at risk for HIV was the target for updating the antiretroviral treatment regimen recommendations.

Incredible resources and effort have been put into the COVID-19 response, but other infectious disease priorities have also been displaced. Patrick Howie, CEO of a firm which aggregates clinical analysis and data, explains.

Rising costs from 2014-2018 may have hindered PrEP expansion, according to a recent retrospective study.

The Roche test supports rapid molecular detection of acute HIV infection, with differentiation between HIV-1 and -2.

Also featuring the latest FDA and global drug development pipeline news.

Dovato can now be used as a complete regimen for treatment of HIV-1 infection to replace an existing ART regimen in adults who are virologically suppressed.

A modeling study from Imperial College shows the COVID-19 pandemic may require balancing with other infectious disease priorities.

Why it's critical for the future of HIV prevention for programs like the California PrEP-AP to reach younger at-risk persons now.

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

How a sexually-transmitted virus is hindered by limited marketing, and how its stigmas compare to those developing around COVID-19.

Why men who have sex with men face social hurdles in seeking PrEP and preventive education.

How regional-based data and advancing preventive options could bolster individual HIV-risk care access.

A study looking at PrEP population obstacles shows men who have sex with men are more likely to not seek out information nor access to prophylaxis.

Dr. Marc Pitasi, epidemiologist, discusses facilitators of routine HIV screening among primary care physicians.

A discussion around new data presented at AIDS 2020 which shows statewide strategies are breaking down barriers.

Investigators in Tanzania trialed modest, automated financial incentives for clinic attendance on viral suppression for patients initiating ART.

How much does the current virus crisis share in common with early HIV outbreak scare?

Investigators compared characteristics and retention between daily and event-driven PrEP patients to better understand low uptake of event-driven PrEP.

Experts assessed the impact of drug overdoses on people living with HIV in British Columbia, identifying factors associated with mortality using competing risk methodology.

People with HIV are living longer than ever at present time, raising quality of life concerns about later stage medical and psychological challenges comorbidities.

The California PrEP Assistance Program, established to remove financial and structural barriers to PrEP access, had positive but uneven initial results.

With fostemsavir now available for patients with few options, an expert discusses what challenges MDR-HIV patients face in their care.

A 34-year-old Brazilian man's HIV was undetectable 57 weeks after ending a heightened regimen of ART.

A look at the BRIGHTE study data which evidenced the recently FDA-approved add-on agent.

In low-level HIV-1 viraemia patients, this strategy demonstrated viral suppression in more than half of a study's participants.

Despite being recommended at least once among all persons aged 13-64 years old by the CDC, notably few respondents have ever been tested for HIV.

Guidelines recommend concentrated adherence counseling and frequent viral load testing for virologic failure, but drug resistance testing is often excluded.

Interim analysis shows a long-acting injectable was associated with fewer HIV infections than daily oral PrEP in a diverse population of HIV-risk participants.

A retrospective analysis of the DRIVE-FORWARD and DRIVE-AHEAD trials shows treatment-naive patients particularly fared well from the novel agent.